(PDF) Tanespimycin Monotherapy in Relapsed Multiple

Tanespimycin Monotherapy in Relapsed Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study

British Journal of Haematology - United Kingdom

doi 10.1111/j.1365-2141.2010.08265.x

Full Text

Abstract

Available in full text

Categories

Date

July 7, 2010

Authors

Paul G. Richardson

Asher A. Chanan-Khan

Marianne Messina

Constantine S. Mitsiades

Kenneth C. Anderson

Publisher

Wiley

Related search

Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

Cancer Research

English

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology

Cancer Research

English

Phase 1b Trial of Pembrolizumab Monotherapy for Relapsed/Refractory Multiple Myeloma: KEYNOTE ‐013

British Journal of Haematology

English

A Phase I Trial of Flavopiridol in Relapsed Multiple Myeloma

Cancer Chemotherapy and Pharmacology

Cancer Research

English

Atacicept in Relapsed/Refractory Multiple Myeloma or Active Waldenström's Macroglobulinemia: A Phase I Study

British Journal of Cancer

Cancer Research

English

Phase 1 Study of the Protein Deubiquitinase Inhibitor VLX1570 in Patients With Relapsed and/or Refractory Multiple Myeloma

Investigational New Drugs

English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology

English

Dose-Escalated Total-Marrow Irradiation (TMI) for Relapsed Multiple Myeloma

International Journal of Radiation Oncology Biology Physics

Cancer Research

Nuclear Medicine

English

Pembrolizumab Combined With Lenalidomide and Low‐dose Dexamethasone for Relapsed or Refractory Multiple Myeloma: Phase I KEYNOTE ‐023 Study

British Journal of Haematology

English